tetano
Editor, Senior Moderator
Intern Med
. 2022;61(10):1561-1565.
doi: 10.2169/internalmedicine.9231-21. Epub 2022 May 15.
Graves' Disease after Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in a Type 1 Diabetes Patient
Mayu Sakai[SUP] 1 2 [/SUP], Ken Takao[SUP] 1 2 [/SUP], Takehiro Kato[SUP] 1 2 [/SUP], Kodai Ito[SUP] 1 2 [/SUP], Sodai Kubota[SUP] 1 2 3 [/SUP], Tokuyuki Hirose[SUP] 1 2 [/SUP], Yanyan Liu[SUP] 1 2 [/SUP], Masami Mizuno[SUP] 1 2 [/SUP], Takuo Hirota[SUP] 1 2 [/SUP], Tetsuya Suwa[SUP] 1 2 [/SUP], Yukio Horikawa[SUP] 1 2 [/SUP], Daisuke Yabe[SUP] 1 2 3 4 5 [/SUP]
Affiliations
Abstract
Although there is a great demand for increased coronavirus disease 2019 (COVID-19) vaccination worldwide, rare side effects of the vaccine in susceptible individuals are attracting attention. We recently treated a patient with type 1 diabetes who had HLA-A*240201/A*020101, B*5401/B*5601, DRB1*0405/DRB1*0405, DPB1*0501/DPB1*0501 and DQB1*0401/DQB1*040 and developed Graves' disease soon after the administration of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. While causal relationships between vaccinations and adverse events are difficult to discern due to both confounding and masking factors, our findings suggest that attention to possible adjuvant-related endocrinological diseases in certain individuals receiving SARS-CoV-2 vaccines is appropriate.
Keywords: Graves' disease; coronavirus disease 2019; type 1 diabetes; vaccination.
. 2022;61(10):1561-1565.
doi: 10.2169/internalmedicine.9231-21. Epub 2022 May 15.
Graves' Disease after Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in a Type 1 Diabetes Patient
Mayu Sakai[SUP] 1 2 [/SUP], Ken Takao[SUP] 1 2 [/SUP], Takehiro Kato[SUP] 1 2 [/SUP], Kodai Ito[SUP] 1 2 [/SUP], Sodai Kubota[SUP] 1 2 3 [/SUP], Tokuyuki Hirose[SUP] 1 2 [/SUP], Yanyan Liu[SUP] 1 2 [/SUP], Masami Mizuno[SUP] 1 2 [/SUP], Takuo Hirota[SUP] 1 2 [/SUP], Tetsuya Suwa[SUP] 1 2 [/SUP], Yukio Horikawa[SUP] 1 2 [/SUP], Daisuke Yabe[SUP] 1 2 3 4 5 [/SUP]
Affiliations
- PMID: 35569928
- DOI: 10.2169/internalmedicine.9231-21
Abstract
Although there is a great demand for increased coronavirus disease 2019 (COVID-19) vaccination worldwide, rare side effects of the vaccine in susceptible individuals are attracting attention. We recently treated a patient with type 1 diabetes who had HLA-A*240201/A*020101, B*5401/B*5601, DRB1*0405/DRB1*0405, DPB1*0501/DPB1*0501 and DQB1*0401/DQB1*040 and developed Graves' disease soon after the administration of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. While causal relationships between vaccinations and adverse events are difficult to discern due to both confounding and masking factors, our findings suggest that attention to possible adjuvant-related endocrinological diseases in certain individuals receiving SARS-CoV-2 vaccines is appropriate.
Keywords: Graves' disease; coronavirus disease 2019; type 1 diabetes; vaccination.
